Tezepelumab Proves Cost-Effective Over Omalizumab in Spanish Severe Asthma Model
A lifetime health economic model indicates tezepelumab is cost-effective or dominant compared to omalizumab for eligible severe uncontrolled allergic asthma ...
A lifetime health economic model indicates tezepelumab is cost-effective or dominant compared to omalizumab for eligible severe uncontrolled allergic asthma ...
A retrospective cohort study found that patients with COPD receiving inhaled corticosteroids experienced a significantly higher pneumonia burden than those ...
Initial findings from the multicenter HS PROGRESS registry reveal significant sex differences in diagnostic delay and disease severity alongside widespread ...
A prospective multicenter cohort study in severe asthma found that SERPINE1 genotype data yielded imprecise, model-dependent estimates that cannot determine ...
A prospective study found that six months of biologic therapy significantly improved quality of life, fatigue, depression, and anxiety in ...
A real-world retrospective study of 20 pediatric patients suggests that subcutaneous infliximab is a feasible maintenance option for IBD, showing ...
A study of 140 participants found elevated interleukin-38 levels in rheumatoid arthritis that correlated with disease activity and susceptibility gene ...
A five-year multicenter retrospective study of 1354 patients across Italy found that tildrakizumab provided sustained real-world effectiveness and high drug ...
In a cross-sectional study of 252 patients with systemic lupus erythematosus, depressive symptoms showed significant indirect associations linking social support ...
A retrospective study of children with juvenile idiopathic arthritis demonstrates that a semi-quantitative ultrasound score reliably evaluates knee synovitis and ...
A clinical trial demonstrates that platelet counts significantly decline alongside disease activity in axial spondyloarthritis patients treated with interleukin-17 or ...
A systematic review and meta-analysis of 21 studies found that ustekinumab achieved a 61 percent 52-week clinical remission rate in ...
A cross-sectional study found that 40 percent of adult severe asthma patients receiving biologic therapy screened positive for possible cognitive ...
A multicentre Italian cohort study found that patients receiving brodalumab for moderate-to-severe plaque psoriasis achieved a median 97.4 percent normalized ...
A multicenter cohort study identifies early biologic therapy, lower body mass index, and fewer baseline tunnels as key predictors of ...
A cross-sectional study finds that Multi-Inflammatory Indices do not significantly distinguish active from inactive ankylosing spondylitis disease states, though they ...
A study of 137 patients found that anti-drug antibodies are associated with lower adalimumab levels and higher disease activity in ...
A 52-week prospective real-world study found that switching to tildrakizumab after anti-IL-17 failure led to sustained clinical improvement and quality ...
A new multiomics-clinical model predicts which psoriasis patients will achieve a 75% reduction in disease severity, identifying HLA-Cw6 genotype and ...
A real-world study finds mepolizumab is associated with reduced healthcare visits and improved symptoms in patients with chronic rhinosinusitis with ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.